[go: up one dir, main page]

NO20081963L - Fremgangsmate for behandling - Google Patents

Fremgangsmate for behandling

Info

Publication number
NO20081963L
NO20081963L NO20081963A NO20081963A NO20081963L NO 20081963 L NO20081963 L NO 20081963L NO 20081963 A NO20081963 A NO 20081963A NO 20081963 A NO20081963 A NO 20081963A NO 20081963 L NO20081963 L NO 20081963L
Authority
NO
Norway
Prior art keywords
ocular neovascular
administration
treating
treatment
methods
Prior art date
Application number
NO20081963A
Other languages
English (en)
Norwegian (no)
Inventor
Richard Anthony Brigandi
Mark Levick
William Henry Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20081963L publication Critical patent/NO20081963L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
NO20081963A 2005-11-29 2008-04-25 Fremgangsmate for behandling NO20081963L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74047805P 2005-11-29 2005-11-29
PCT/US2006/045776 WO2007064752A2 (fr) 2005-11-29 2006-11-29 Procede de traitement

Publications (1)

Publication Number Publication Date
NO20081963L true NO20081963L (no) 2008-08-26

Family

ID=38037895

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081963A NO20081963L (no) 2005-11-29 2008-04-25 Fremgangsmate for behandling

Country Status (27)

Country Link
US (1) US20080293691A1 (fr)
EP (2) EP1968594B1 (fr)
JP (1) JP5180834B2 (fr)
KR (1) KR20080071188A (fr)
CN (1) CN101370505B (fr)
AT (1) ATE482708T1 (fr)
AU (2) AU2006320535B2 (fr)
BR (1) BRPI0619057A2 (fr)
CA (1) CA2631173A1 (fr)
CR (1) CR10010A (fr)
CY (1) CY1111047T1 (fr)
DE (1) DE602006017261D1 (fr)
DK (1) DK1968594T3 (fr)
EA (1) EA016227B1 (fr)
ES (2) ES2350858T3 (fr)
HR (1) HRP20100559T1 (fr)
IL (1) IL191027A0 (fr)
MA (1) MA30044B1 (fr)
MX (1) MX2008006379A (fr)
MY (1) MY144750A (fr)
NO (1) NO20081963L (fr)
NZ (1) NZ568075A (fr)
PL (1) PL1968594T3 (fr)
PT (1) PT1968594E (fr)
SI (1) SI1968594T1 (fr)
UA (1) UA94427C2 (fr)
WO (1) WO2007064752A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069576A1 (fr) 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Compositions therapeutiques utilisees pour le traitement des affections inflammatoires oculaires
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
JP2012533562A (ja) * 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
WO2011050159A1 (fr) * 2009-10-23 2011-04-28 Glaxo Wellcome Manufacturing Pte Ltd Compositions et procédés
WO2011058179A1 (fr) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5-(4-(n-(2,3-diméthyl-2h-indazol-6-yl)-n-méthylamino)pyrimidin-2-ylamino)-2-méthylbenzènesulfonamide
WO2011069053A1 (fr) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Procede de preparation de pazopanip hcl et formes cristallines de pazopanib hcl
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
WO2013022801A1 (fr) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Administration de petites molécules à l'aide d'un dispositif thérapeutique implantable
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
EP2600930B1 (fr) 2010-08-05 2021-02-17 ForSight Vision4, Inc. Appareil d'injection pour l'administration de médicaments
US20120129847A1 (en) * 2010-10-07 2012-05-24 Kevin Gene Peters Compositions and methods for treating ocular edema, neovascularization and related diseases
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
CA2840491A1 (fr) 2011-06-28 2013-01-03 Bayer Healthcare Llc Composition pharmaceutique topique ophtalmologique contenant du sorafenib
WO2013000917A1 (fr) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Composition pharmaceutique topique ophtalmologique contenant du régorafénib
HUE054578T2 (hu) 2011-09-16 2021-09-28 Forsight Vision4 Inc Fluidumcserélõ berendezés
CN104254249B (zh) * 2011-10-31 2017-02-15 诺华股份有限公司 帕唑帕尼制剂
AU2012343759A1 (en) 2011-12-01 2014-06-26 Glaxo Group Limited Methods of treatment and prevention of eye diseases
CN102657655B (zh) * 2012-05-17 2014-05-21 大连理工大学 嘧啶胺类化合物在制备乙酰胆碱酯酶抑制剂中的应用
CN104582685A (zh) 2012-06-25 2015-04-29 拜尔健康护理有限责任公司 含有舒尼替尼的局部眼科药物组合物
WO2014097152A1 (fr) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Procédé de préparation du pazopanib ou de ses sels
US9802923B2 (en) 2012-12-17 2017-10-31 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2014152959A1 (fr) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systèmes pour l'administration intra-oculaire entretenue de composés à faible solubilité provenant d'un implant de système de pose d'orifice
GB2516561B (en) 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
CA2907681C (fr) 2013-03-28 2022-11-22 Forsight Vision4, Inc. Implant ophtalmique pour administrer des substances therapeutiques
WO2015068175A2 (fr) 2013-11-05 2015-05-14 Laurus Labs Private Limited Procédé perfectionné de préparation de pazopanib ou d'un sel de qualité pharmaceutique de celui-ci
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN107106551A (zh) 2014-08-08 2017-08-29 弗赛特影像4股份有限公司 受体酪氨酸激酶抑制剂的稳定且可溶的制剂和其制备方法
CA2960583C (fr) * 2014-09-09 2019-01-15 Arturo Solis Herrera Procedes de traitement et de prevention de maladies, de troubles et d'affections oculaires avec de la melanine et des analogues, des precurseurs, et des derives de melanine
BR112017009660A2 (pt) 2014-11-10 2017-12-19 Forsight Vision4 Inc dispositivos de administração de fármacos expansíveis e métodos de utilização
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3399999A4 (fr) * 2016-01-07 2020-03-11 The Schepens Eye Research Institute, Inc. Thérapeutique pour maladies immuno-inflammatoires oculaires
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
CN106565688B (zh) * 2016-11-11 2018-08-31 重庆医科大学 帕唑帕尼二聚体及其制备方法和用途
US11912754B2 (en) 2017-10-12 2024-02-27 Immunowake Inc. VEGFR-antibody light chain fusion protein
JP7314155B2 (ja) 2017-11-21 2023-07-25 フォーサイト・ビジョン４・インコーポレーテッド 膨張可能ポート送達システムのための流体交換装置及びその使用方法
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
DE3905050A1 (de) 1989-02-18 1990-08-30 Lohmann Therapie Syst Lts Therapeutisches system zur verzoegerten und gesteuerten transdermalen oder transmucosalen verabreichung von wirkstoffen (ii)
US4946450A (en) 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5290892A (en) 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2690846B1 (fr) 1992-05-05 1995-07-07 Aiache Jean Marc Forme galenique pour administration oculaire et procede de preparation.
WO1995003009A1 (fr) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Methode de traitement de la degenerescence maculaire
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5710165A (en) 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
AUPM897594A0 (en) 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
DK0788351T3 (da) 1994-11-10 2003-05-26 Univ Kentucky Res Found Implanterbar, genopfyldelig anordning til hastighedsreguleret lægemiddeladministration direkte til en indre del af kroppen
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5743274A (en) 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US5824073A (en) 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
US20030125317A1 (en) * 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
AU738338B2 (en) 1997-08-11 2001-09-13 Allergan, Inc. Sterile bioerodible implant device with improved biocompatability and method
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6146366A (en) 1998-11-03 2000-11-14 Ras Holding Corp Device for the treatment of macular degeneration and other eye disorders
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6660960B2 (en) 1999-12-28 2003-12-09 K. K. Endo Seisakusho Method for manufacturing golf club
DK1313415T3 (da) 2000-08-30 2008-10-13 Univ Johns Hopkins Indretninger til intraokulær lægemiddeladministration
ATE430742T1 (de) * 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
US7592016B2 (en) 2001-06-28 2009-09-22 Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US7749528B2 (en) 2001-08-29 2010-07-06 Ricardo Azevedo Pontes De Carvalho Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
ES2393101T3 (es) 2001-08-29 2012-12-18 Ricardo A. P. De Carvalho Sistema implantable y sellable para la administración unidireccional de agentes terapéuticos a tejidos diana
PL373787A1 (en) * 2002-05-03 2005-09-19 Alcon Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
WO2003106416A2 (fr) * 2002-06-17 2003-12-24 Smithkline Beecham Corporation Processus chimique
WO2005105094A2 (fr) * 2004-04-16 2005-11-10 Smithkline Beecham Corporation Methode de traitement du cancer
EP2324848A3 (fr) * 2004-10-21 2011-09-14 Genentech, Inc. Méthode de traitement de maladies intraoculaires néovasculaires
WO2006117666A2 (fr) * 2005-04-29 2006-11-09 Pfizer Inc. Formes posologques, compositions pharmaceutiques et methodes d'administration sous la capsule de tenon

Also Published As

Publication number Publication date
CA2631173A1 (fr) 2007-06-07
WO2007064752A3 (fr) 2008-08-14
AU2006320535A1 (en) 2007-06-07
EP1968594B1 (fr) 2010-09-29
WO2007064752A2 (fr) 2007-06-07
MX2008006379A (es) 2009-03-03
CR10010A (es) 2008-11-03
EP1968594A2 (fr) 2008-09-17
HK1121386A1 (en) 2009-04-24
KR20080071188A (ko) 2008-08-01
NZ568075A (en) 2010-12-24
AU2006320535B2 (en) 2010-09-23
CN101370505B (zh) 2012-03-21
CY1111047T1 (el) 2015-06-11
DK1968594T3 (da) 2010-12-13
UA94427C2 (ru) 2011-05-10
PL1968594T3 (pl) 2011-03-31
MA30044B1 (fr) 2008-12-01
IL191027A0 (en) 2009-08-03
ES2392030T3 (es) 2012-12-04
EP2329821B1 (fr) 2012-08-22
ATE482708T1 (de) 2010-10-15
EA200801168A1 (ru) 2008-10-30
HRP20100559T1 (hr) 2010-11-30
DE602006017261D1 (de) 2010-11-11
US20080293691A1 (en) 2008-11-27
JP5180834B2 (ja) 2013-04-10
SI1968594T1 (sl) 2011-01-31
MY144750A (en) 2011-10-31
JP2009517396A (ja) 2009-04-30
EA016227B1 (ru) 2012-03-30
ES2350858T3 (es) 2011-01-27
EP2329821A1 (fr) 2011-06-08
BRPI0619057A2 (pt) 2011-09-20
CN101370505A (zh) 2009-02-18
AU2010249187A1 (en) 2011-01-06
PT1968594E (pt) 2010-11-18

Similar Documents

Publication Publication Date Title
NO20081963L (no) Fremgangsmate for behandling
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
TW200716139A (en) Methods and compositions for managing psychotic disorders
BR0316169A (pt) Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
PL2530083T3 (pl) Inhibitory kinazy tyrozynowej brutona
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
CY1111390T1 (el) Μεθοδος θεραπευτικης αγωγης καρκινου
WO2007143483A3 (fr) Procédé de traitement du cancer
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
NO20071704L (no) Prostaglandinderivater for behandling av gastrointestinal forstyrrelse
NO20052059L (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
MY128882A (en) Novel use of substituted aminomethyl chromans
EA200500242A1 (ru) Пиперидин-2,5-дионовые памоатные соли и их использование для лечения связанных со стрессом аффективных расстройств

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application